ABEONA THERAPEUTICS INC.
ABEODrugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
ofloxacin
Diabetic Foot Ulcers
EB-101
Epidermolysis Bullosa
EB-101 Surgical application of RDEB wounds
Epidermolysis Bullosa
MSI-78
Diabetic Foot Ulcers
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Onychomycosis
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Epidermolysis Bullosa Dystrophica
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ofloxacin | Phase 3 | Diabetic Foot Ulcers | - | |
EB-101 | Phase 3 | Epidermolysis Bullosa | - | - |
EB-101 Surgical application of RDEB wounds | Phase 3 | Epidermolysis Bullosa | - | - |
MSI-78 | Phase 3 | Diabetic Foot Ulcers | - | - |
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) | Phase 2 | Onychomycosis | - | - |
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Phase 2 | Epidermolysis Bullosa Dystrophica | - | - |
Diabetic Foot Ulcers
2 drugs in this indication
Epidermolysis Bullosa
2 drugs in this indication
Onychomycosis
1 drug in this indication
Epidermolysis Bullosa Dystrophica
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)